NineSigma, representing a Japanese pharmaceutical company with an expertise in bone-related diseases as one of their future focal areas, seeks a potential collaboration partner(s) that possess drug discovery seeds or molecular targets for rare diseases involving bones and growth plate cartilage.
Through collaboration with a potential partner(s), the client ultimately aims to develop an innovative drug that meets unmet medical needs in the area of bone-related diseases.
The client seeks drug discovery seeds or molecular targets of required drug efficacy and effects should expected the increase in bone mass (increased calcification), bone growth and bone mass loss (Including effects on ectopic calcification).
Submissions to this Challenge must be received by Aug 2, 2020.
Source: NineSights